Actively Recruiting
A Study to Evaluate Safety and Efficacy of Bomedemstat (MK-3543-017)
Led by Merck Sharp & Dohme LLC · Updated on 2026-04-02
400
Participants Needed
21
Research Sites
549 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The primary purpose of the study is to transition participants into an extension study to collect long-term safety and efficacy data. The study will include participants who are safely tolerating bomedemstat, receiving clinical benefit from its use in estimation of the investigator, and have shown the following criteria: * Participants from the IMG-7289-202/MK-3543-005 (NCT05223920) study must have received at least 6 months of treatment with bomedemstat; * Essential thrombocythemia (ET) and polycythemia vera (PV) participants from studies other than IMG-7289-202/MK-3543-005 must have achieved confirmed hematologic remission. No hypothesis testing will be conducted in this study.
CONDITIONS
Official Title
A Study to Evaluate Safety and Efficacy of Bomedemstat (MK-3543-017)
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Is from a bomedemstat study sponsored by Imago BioSciences, Inc. (a subsidiary of Merck & Co., Inc.) or MSD, and established by the Sponsor as MK-3543-017 ready
- Has received at least 6 months of treatment with bomedemstat in the IMG-7289-202/MK-3543-005 study, while safely tolerating bomedemstat, and receiving clinical benefit from its use in the estimation of the investigator
- ET and PV participants from established feeder studies other than IMG-7289- 202/MK-3543-005 must have achieved confirmed hematologic remission, must be safely tolerating bomedemstat, and must be receiving clinical benefit from its use in the estimation of the investigator
- Is not currently on a dose hold
- Participant must be able to swallow oral medication and follow instructions for at-home dosing of bomedemstat
You will not qualify if you...
- Has received prohibited concomitant medications
- Ongoing or planned participation in another investigational study
- Has noncompliance in prior bomedemstat study receiving <90% of assigned doses excluding suspensions or holds as assigned by the investigator
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 21 locations
1
University of Michigan ( Site 6000)
Ann Arbor, Michigan, United States, 48109
Actively Recruiting
2
DUHS Duke Blood Cancer Center ( Site 6005)
Durham, North Carolina, United States, 27705
Actively Recruiting
3
The James Cancer Hospital and Solove Research Institute at The Ohio State University Comprehensive C ( Site 6007)
Columbus, Ohio, United States, 43210
Actively Recruiting
4
UPMC Hillman Cancer Center ( Site 6004)
Pittsburgh, Pennsylvania, United States, 15232
Actively Recruiting
5
Royal Prince Alfred Hospital ( Site 1003)
Camperdown, New South Wales, Australia, 2050
Actively Recruiting
6
Royal North Shore Hospital ( Site 1001)
St Leonards, New South Wales, Australia, 2065
Actively Recruiting
7
Sunshine Coast Hematology and Oncology Clinic ( Site 1006)
Buderim, Queensland, Australia, 4556
Actively Recruiting
8
Gold Coast University Hospital-Cancer and Blood Disorders Clinical Trial Team ( Site 1002)
Southport, Queensland, Australia, 4215
Actively Recruiting
9
Royal Adelaide Hospital-Haematology Clinical Trials Unit ( Site 1000)
Adelaide, South Australia, Australia, 5000
Actively Recruiting
10
Monash Health ( Site 1004)
Clayton, Victoria, Australia, 3168
Actively Recruiting
11
Queen Mary Hospital ( Site 1601)
Hksar, Hong Kong
Active, Not Recruiting
12
Azienda Ospedaliera Universitaria Careggi ( Site 2700)
Florence, Tuscany, Italy, 50134
Actively Recruiting
13
Azienda Ospedaliero-Universitaria SS. Antonio e Biagio e Cesare Arrigo ( Site 2703)
Alessandria, Italy, 15121
Actively Recruiting
14
IRCCS Azienda Ospedaliero-Universitaria di Bologna, Policlinico di Sant'Orsola ( Site 2702)
Bologna, Italy, 40138
Actively Recruiting
15
Ospedale di Circolo e Fondazione Macchi Varese ( Site 2701)
Varese, Italy, 21100
Actively Recruiting
16
North Shore Hospital-Department of Haematology ( Site 1401)
Auckland, New Zealand, 0622
Active, Not Recruiting
17
Aotearoa Clinical Trials ( Site 1400)
Auckland, New Zealand, 2025
Active, Not Recruiting
18
Imperial College Healthcare NHS Trust - Hammersmith Hospital ( Site 3402)
London, Hammersmith and Fulham, United Kingdom, W12 0HS
Actively Recruiting
19
Boston Pilgrim Hospital ( Site 3403)
Boston, Lincolnshire, United Kingdom, PE21 9QS
Actively Recruiting
20
University College London Hospital ( Site 3400)
London, London, City of, United Kingdom, NW1 2PG
Actively Recruiting
21
Guy's & St Thomas' NHS Foundation Trust ( Site 3401)
London, London, City of, United Kingdom, SE1 9RT
Actively Recruiting
Research Team
T
Toll Free Number
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here